Wisconsin

Global health R&D delivers for Wisconsin

Click here to select a new state

Select a new state

US government investment in global health R&D has delivered

$191.3 milion

to Wisconsin research institutions

2,500+ new jobs

for Wisconsin

Wisconsin's top USG-funded global health R&D institutions

University of Wisconsin-Madison

$160.1 million

Medical College of Wisconsin

$15.1 million

Godx Inc.

$4.6 million

ioGenetics LLC

$4 million

Lucigen Corporation*

$2.2 million

Salus Discovery

$1.5 million

Versiti Blood Center of Wisconsin

$1.5 million

Concordia University Wisconsin

$488 thousand

Scarab Genomics LLC

$470 thousand

Cascade Biosystems Inc.

$448 thousand

BellBrook Labs

$422 thousand

Intuitive Biosciences

$300 thousand

Terra Bioforge (formerly Varigen Biosciences Corporation)

$268 thousand

DNASTAR Inc. (formerly DNASTAR Bioinformatics Software)

$12 thousand

Marshfield Clinic Research Institute

$12 thousand

Wisconsin's top areas of global health R&D by USG funding

14%

COVID-19

4.6%

Diarrheal diseases

4.7%

Flioviral diseases (including Ebola, Marburg)

25.1%

HIV/AIDS

2.1%

Malaria

11.4%

Neglected tropical diseases

Dengue

Helminth infections (Worms & Flukes)

Kinetoplastid diseases

2.8%

Salmonella infections

15.5%

Tuberculosis

12.6%

Zika

7.3%

Other

Arenaviral hemorrhagic fevers (including Lassa fever)

Bacterial pneumonia & meningitis

Cryptococcal meningitis

Multi-disease/health area R&D

Other coronaviruses (including MERS, SARS)

Reproductive health

Neglected and emerging diseases in Wisconsin

Chikungunya cases

Dengue cases

HIV diagnoses

10412

Malaria cases

Mpox cases

239

Tuberculosis cases

1802

Global health R&D at work in Wisconsin

University of Wisconsin at Madison scientists are leading a research consortium focused on developing a pan-coronavirus vaccine that could protect against multiple known and yet-unknown coronaviruses. The consortium was one of three teams chosen by the US National Institutes of Health to simultaneously work on this goal. Coronaviruses are the viral family responsible for not only the COVID-19 pandemic but also the epidemics of Middle East respiratory syndrome (MERS) and severe acute respiratory syndrome (SARS). A pan-coronavirus vaccine is an important tool that would offer some level of protection to populations if a new coronavirus epidemic or pandemic occurs, buying scientists time to develop a pathogen-specific vaccine.

Footnotes

Methodology
US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
*Organization appears to be closed/out of business.
Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
Case study photo: US Department of Energy